Most drugs likely to be selected for Medicare price negotiation have low therapeutic benefit, study finds

(By Rylee Wilson for Becker’s Hospital Review)

Seven of the 10 drugs most likely to be selected for Medicare price negotiation were rated as having low clinical value by health technology assessment organizations outside the U.S., a study published in JAMA found. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org